Stereoselective synthesis from a process research perspective.
The process chemists' primary responsibility is to develop efficient and reproducible syntheses of pharmaceutically active compounds. This task is complicated when dealing with chiral molecules that often must be made as single isomers according to regulatory guidelines. The presence of any isomeric impurity in the final product, even in small amounts, is usually not acceptable. This requirement necessitates an exquisite understanding of the methods employed in the construction of chiral drugs. However, the chemistry available for this purpose is sometimes limited and often requires a significant amount of effort and creativity to be made both functional and consistent.
Hillier
Michael C
MC
Department of Process Research, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. michael_hillier@merck.com
Reider
Paul J
PJ
D000818:Animals; D015780:Carbapenems / Q000138:chemical synthesis / Q000494:pharmacology; D020650:Combinatorial Chemistry Techniques; D065128:Endothelin Receptor Antagonists; D006801:Humans; D007189:Indans / Q000138:chemical synthesis / Q000737:chemistry; D018727:Muscarinic Antagonists / Q000138:chemical synthesis / Q000494:pharmacology; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis* / Q000737:chemistry; D010880:Piperidines / Q000138:chemical synthesis / Q000494:pharmacology; D013237:Stereoisomerism; D013373:Substance P / Q000037:antagonists & inhibitors / Q000737:chemistry
D015780:Carbapenems; D065128:Endothelin Receptor Antagonists; D007189:Indans; D018727:Muscarinic Antagonists; D004364:Pharmaceutical Preparations; D010880:Piperidines; D013373:Substance P; C013352:indacrinone